Background: Cardiovascular disease (CVD) is a common comorbidity in people with asthma. However, safety concerns have caused heterogeneity in clinical guideline recommendations over the use of cardioselective beta-blockers in people with asthma and CVD, partly because risk in the general population has been poorly quantified. The aim of this study was to measure the risk of asthma exacerbations with beta-blockers prescribed to a general population with asthma and CVD.
Methods: Linked data from the UK Clinical Practice Research Datalink was used to perform nested case-control studies among people with asthma and CVD matched on age, sex and calendar time. Adjusted incidence rate ratios (IRR) were calculated for the association between oral beta-blocker use and moderate asthma exacerbations (rescue oral steroids) or severe asthma exacerbations (hospitalisation or death) using conditional logistic regression.
Results: The cohort consisted of 35,502 people identified with active asthma and CVD, of which 14.1% and 1.2% were prescribed cardioselective and non-selective beta-blockers, respectively, during follow-up. Cardioselective beta-blocker use was not associated with a significantly increased risk of moderate or severe asthma exacerbations. Consistent results were obtained following sensitivity analyses and a self-controlled case series approach. In contrast, non-selective beta-blockers were associated with a significantly increased risk of moderate asthma exacerbations when initiated at low to moderate doses (IRR 5.16, 95% CI 1.83-14.54, P = 0.002), and both moderate and severe exacerbations when prescribed chronically at high dose (IRR 2.68, 95% CI 1.08-6.64, P = 0.033 and IRR 12.11, 95% CI 1.02-144.11, P = 0.048, respectively).
Conclusions: Cardioselective beta-blockers prescribed to people with asthma and CVD were not associated with a significantly increased risk of moderate or severe asthma exacerbations and potentially could be used more widely when strongly indicated.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270217 | PMC |
| http://dx.doi.org/10.1186/s12916-017-0781-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact analysis of infant antibiotic exposure on the burden of asthma: a simulation modeling study.
Front Allergy
December 2024
Respiratory Evaluation Sciences Program, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
Background: Infant antibiotic use is associated with increased risk of asthma. We examined the population impact of antibiotic exposure in the first year of life on the burden of pediatric asthma in British Columbia, Canada, using simulation modeling.
Methods: We performed a Bayesian meta-analysis of empirical studies to construct dose-response equations between antibiotic exposure in the first year of life and pediatric (<19 years of age) asthma.
In severe asthma with an eosinophilic phenotype, depemokimab improved exacerbations, but not quality of life, at 52 wk.
Ann Intern Med
January 2025
Austin Hospital and University of Melbourne, Melbourne, Victoria, Australia (C.F.M.).
GIM/FP/GP: [Formula: see text] Allerg & Immunol: [Formula: see text] Pulmonology: [Formula: see text].
View Article and Find Full Text PDFThe Correlation Between Airborne Pollen and Sensitization in Children with Respiratory Allergic Diseases: A Cross-Sectional Study.
J Asthma Allergy
December 2024
Department of Allergy and Clinical Immunology, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China.
Background: Pollen is a significant contributor to respiratory allergies worldwide, underscoring the importance of understanding its association with childhood sensitization to enhance clinical management.
Objective: This study focuses on investigating the prevalence of various airborne pollens and their correlation with clinical characteristics of childhood respiratory allergic diseases in southeastern China.
Methods: From November 2020 to October 2021, this research employed Durham monitoring samplers to collect airborne pollen.
[Thunderstorm asthma: current status and perspectives].
Zhonghua Jie He He Hu Xi Za Zhi
January 2025
Department of Pulmonary and Critical Care Medicine, NHC Key Laboratory of Diagnosis & Treatment of COPD/Inner Mongolia Key Laboratory of Respiratory Diseases, Inner Mongolia People's Hospital, Hohhot010017, China.
Thunderstorm asthma refers to the acute exacerbation of asthma triggered by extreme weather events, which poses life-threatening risks due to severe asthma attacks and strained medical resources. Recent climate changes, including global warming, the greenhouse effect, and increased carbon emissions, have increased the levels of environmental allergens, contributing to a higher incidence of asthma and other allergic diseases. In addition, the increasing frequency of thunderstorms has exacerbated the impact of thunderstorm asthma.
View Article and Find Full Text PDFGut feelings on short-chain fatty acids to regulate respiratory health.
Trends Endocrinol Metab
January 2025
School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK. Electronic address:
Respiratory infections and diseases pose significant challenges to society and healthcare systems, underscoring the need for preventative and therapeutic strategies. Recent research in rodent models indicates that short-chain fatty acids (SCFAs), metabolites produced by gut bacteria, may offer medicinal benefits for respiratory conditions. In this opinion, we summarize the current literature that highlights the potential of SCFAs to enhance immune balance in humans.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!